EGFR and non-small cell lung carcinoma: To investigate the correlation of miR‐641 expression level and EGFR‐TKI resistance in NSCLC patients, we measured the expression of miR‐641 in 18 human EGFR‐mutant NSCLC samples that acquired resistance to erlotinib treatment compared with matched pretreatment samples.